Ingredients, reviews, and professional insight for NZ beauty
Peptides have quietly become the ingredient every serum wants on its front label, sitting somewhere between the hard evidence of retinoids and the soft promise of a nicer texture. They are real molecules doing real things. The question worth answering, before you hand over $180 at a Newmarket counter, is which things – and which things they cannot do.
A peptide is a short chain of amino acids, usually somewhere between two and fifty of them linked in sequence. Chain them into the hundreds and you have a protein. Collagen is a protein. Elastin is a protein. Peptides are the fragments, not the finished structure.
That distinction explains why a collagen cream is close to pointless and a peptide serum is not automatically so. Collagen molecules are far too large to get anywhere useful from the surface of the skin. Peptides are small enough that the conversation is worth having, which is a lower bar than the advertising implies, but a real one.
Skin is a barrier before it is anything else. The stratum corneum, the outermost layer of flattened dead cells held in a lipid matrix, exists to keep things out. Most peptides are water-loving and, by skincare standards, still bulky, which makes them poor candidates for the crossing.
Formulators get around this by bolting a fatty acid tail onto the peptide. That is what the palmitoyl prefix means on an ingredient list: a lipid handle that helps the molecule slip through a lipid layer.
It works well enough to be worth doing. Whether it works well enough to reach the living dermis in useful quantities is a question the category has never quite settled.

Signal peptides are the biggest group on the shelf and carry most of the ad copy. The mechanism is genuinely clever. When collagen breaks down it leaves characteristic fragments behind, and skin appears to read those fragments as damage worth repairing. A signal peptide is a synthetic copy of that message, applied in the hope of a response without the damage.
Palmitoyl pentapeptide-4, better known as Matrixyl, is the one you will meet most often. The supporting studies tend to be small, funded by the ingredient houses selling the material, and measure changes that are real but modest. A few percent of wrinkle depth over months is not a different face.
Carrier peptides do a different job. They ferry a trace mineral to where an enzyme needs it, and in practice that means copper peptides, specifically GHK-Cu: a three-amino-acid chain bound to copper that emerged from wound-healing research in the 1970s and has had a devoted following since.
That research is legitimate. The leap to firmer, smoother skin on an intact face is the part requiring faith. GHK-Cu sits at the sharper end of the price range and does not sit comfortably alongside strong acids or high-strength vitamin C, so it wants its own slot in a routine. Plenty of people find that inconvenient enough to skip it.
Acetyl hexapeptide-8, sold as Argireline, is the headline act in this class, and it rarely appears without a nudge toward a certain injectable this site does not cover. The comparison overreaches badly. These peptides are thought to interfere slightly with the signalling that contracts facial muscles – applied to the surface of skin built to stop things reaching muscle.
What the evidence supports is a small, temporary softening of fine expression lines in some people, most visibly around the eyes, and only while use continues. What it does not support is anything approaching a clinical outcome. If that is what you are after, that conversation belongs with a qualified practitioner, not a serum.
The fourth class works from the other direction. Rather than asking skin to make more collagen, enzyme-inhibiting peptides aim to slow the enzymes that break existing collagen down, chiefly the matrix metalloproteinases that UV exposure and inflammation ramp up. Soy and rice-derived peptides turn up here most often.
It is the least glamorous claim in the category and possibly the most sensible one. Preserving what you have is easier than manufacturing more. It is also the hardest to notice, because nobody sees the damage that did not happen, and it is comprehensively outperformed by the thing that stops those enzymes firing in the first place, which is sunscreen.

This is the part the marketing skirts. Peptides against retinol is not a fair fight on evidence. Retinoids have decades of independent published research and a mechanism understood down to the receptor. Vitamin C, in a stable form at a sensible pH, is not far behind.
Peptides have a thinner file: fewer independent trials, smaller sample sizes, shorter durations, and heavy reliance on studies run by the companies selling the raw material. That does not make them useless. It makes them a reasonable addition rather than a foundation, and it means the honest framing is that evidence supports a modest effect, not that the matter is settled.
Peptides are used at fractions of a percent, which means the name on the front of the box tells you very little. What matters is whether the peptide survives the formula it is sitting in. Many are unstable at low pH, so a peptide parked in the same bottle as a strong acid is likely doing less than the label implies. Water-based formulas need proper preservation, and open jars do peptides no favours.
That is why two serums built around the same headline ingredient can behave completely differently, and why the more useful question is never which peptide, but who formulated it and how it is packaged.
The sensible position is peptides as a supporting player. They are well tolerated, they rarely sting, and they do not make skin more sensitive to UV, which makes them a genuinely useful option for people whose skin will not put up with retinoids, or who are pregnant and have been advised off them.
Used alongside a retinoid rather than instead of one, they are a reasonable layer of insurance. Used instead of sunscreen, they are decorative. Results vary between people in ways nobody can predict from an ingredient list, and whatever you do notice will arrive over months rather than weeks.

The entry tier runs roughly $15 to $35 and lives at Chemist Warehouse, Farmers and the supermarket beauty aisle: The Ordinary’s Matrixyl and Buffet formulas, The Inkey List, Olay Regenerist. These are honest products at honest prices, and the peptides in them are the same raw materials the expensive brands buy.
The middle tier, $60 to $130, is where formulation starts to earn its keep. Medik8, Emma Lewisham and the clinic brands stocked through New Zealand beauty therapists sit here. Above $150 you are largely paying for texture, packaging and the counter experience.
The peptide itself does not get better with price. The formula around it sometimes does.
Ingredient lists are a legal requirement rather than a courtesy, since cosmetics sold in New Zealand sit under the Environmental Protection Authority’s rules for cosmetic products.
Peptides sit low in the list by nature, because they are used at low concentrations, so position on its own tells you nothing. Their company tells you plenty. A peptide listed after the fragrance and the preservative is there in trace amounts, and a formula naming five different peptides is usually spreading a small budget thinly.
If your skin is genuinely reactive, or something is not settling, that is a GP or dermatologist conversation rather than a serum one.
Peptides are a decent ingredient sold with an indecent amount of confidence. Somewhere between the collagen cream that cannot work and the retinoid that demonstrably does, they occupy a real but unglamorous middle: worth having in a routine, not worth reorganising one around. Buy the formula, not the front of the box.